Meta-analysis: Underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 7, 2013, Pages 703-712

  Tan, D ^a   Yopp, A ^b,c   Beg, M S ^b,c   Gopal, P ^b   Singal, A G ^b,c  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; ETHNICITY; HEALTH CARE DISPARITY; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LOWEST INCOME GROUP; META ANALYSIS; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; SYSTEMATIC REVIEW; UNITED STATES;

AGED; CARCINOMA, HEPATOCELLULAR; HEALTHCARE DISPARITIES; HUMANS; LIVER NEOPLASMS; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 84883485745     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12450     Document Type: Article

References (47)

1. El-Serag HB, Rudolph KL,. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
2. Bruix J, Sherman M,. Management of hepatocellular carcinoma: an update. Hepatology 2010; 53: 1-35.
3. Lopez PM, Villanueva A, Llovet JM,. Systematic review: evidence-based management of hepatocellular carcinoma-an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006; 23: 1535-47.
4. Artinyan A, Mailey B, Sanchez-Luege N, et al,. Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States. Cancer 2010; 116: 1367-77.
5. Decker KM, Harrison M, Chateau D,. Influence of direct referrals on time to diagnosis after an abnormal breast screening result. Cancer Detect Prev 2004; 28: 361-7.
6. Sloane D, Chen H, Howell C,. Racial disparity in primary hepatocellular carcinoma: tumor stage at presentation, surgical treatment and survival. J Natl Med Assoc 2006; 98: 1934-9.
7. Davila JA, El-Serag HB,. Racial differences in survival of hepatocellular carcinoma in the United States: a population-based study. Clin Gastroenterol Hepatol 2006; 4: 104-10.
8. Siegel AB, McBride RB, El-Serag HB, et al,. Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998-2002. Am J Gastroenterol 2008; 103: 120-7.
9. Altekruse SF, McGlynn KA, Dickie LA, Kleiner DE,. Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008. Hepatology 2012; 55: 476-82.
10. Cance WG, Stewart AK, Menck HR,. The National Cancer Data Base Report on treatment patterns for hepatocellular carcinomas: improved survival of surgically resected patients, 1985-1996. Cancer 2000; 88: 912-20.
11. Harrison LE, Reichman T, Koneru B, et al,. Racial discrepancies in the outcome of patients with hepatocellular carcinoma. Arch Surg 2004; 139: 992-6.
12. Jan T, Medvedev S, Cannon RM, et al,. Racial disparity and their impact on hepatocellular cancer outcomes in inner-city New Orleans. Surgery 2012; 152: 661-6.
13. Jou JH, Chen PH, Jazwinski A, Bouneva I, Smith AD, Muir AJ,. Rates of surveillance and management of hepatocellular carcinoma in patients evaluated at a liver transplant center. Dig Dis Sci 2010; 55: 3591-6.
14. Kemmer N, Neff G, Secic M, Zacharias V, Kaiser T, Buell J,. Ethnic differences in hepatocellular carcinoma: implications for liver transplantation. Dig Dis Sci 2008; 53: 551-5.
15. Kitisin K, Packiam V, Steel J, et al,. Presentation and outcomes of hepatocellular carcinoma patients at a western centre. HPB (Oxford) 2011; 13: 712-22.
16. Kooby DA, Egnatashvili V, Graiser M, et al,. Changing management and outcome of hepatocellular carcinoma: evaluation of 501 patients treated at a single comprehensive center. J Surg Oncol 2008; 98: 81-8.
17. Kozyreva ON, Chi D, Clark JW, et al,. A multicenter retrospective study on clinical characteristics, treatment patterns, and outcome in elderly patients with hepatocellular carcinoma. Oncologist 2011; 16: 310-8.
18. Leykum LK, El-Serag HB, Cornell J, Papadopoulos KP,. Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival. Clin Gastroenterol Hepatol 2007; 5: 508-12.
19. Sanyal A, Poklepovic A, Moyneur E, Barghout V,. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin 2010; 26: 2183-91.
20. Sarkar M, Stewart S, Yu A, Chen MS, Nguyen TT, Khalili M,. Hepatocellular carcinoma screening practices and impact on survival among hepatitis B-infected Asian Americans. J Viral Hepat 2012; 19: 594-600.
21. Schwartz ME, Sung M, Mor E, et al,. A multidisciplinary approach to hepatocellular carcinoma in patients with cirrhosis. J Am Coll Surg 1995; 180: 596-603.
22. Shah SA, Smith JK, Li Y, Ng SC, Carroll JE, Tseng JF,. Underutilization of therapy for hepatocellular carcinoma in the medicare population. Cancer 2011; 117: 1019-26.
23. Stravitz RT, Heuman DM, Chand N, et al,. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med 2008; 121: 119-26.
24. Stuart KE, Anand AJ, Jenkins RL,. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 1996; 77: 2217-22.
25. Theodoropoulos J, Brooks A,. Inconsistency in the management of patients with hepatocellular carcinoma: the need for a strict protocol. Am Surg 2011; 77: 207-14.
26. Tong MJ, Chavalitdhamrong D, Lu DS, et al,. Survival in Asian Americans after treatments for hepatocellular carcinoma: a seven-year experience at UCLA. J Clin Gastroenterol 2010; 44: e63-70.
27. Wong LL, Hernandez B, Kwee S, Albright CL, Okimoto G, Tsai N,. Healthcare disparities in Asians and Pacific Islanders with hepatocellular cancer. Am J Surg 2012; 203: 726-32.
28. Yang JD, Harmsen WS, Slettedahl SW, et al,. Factors that affect risk for hepatocellular carcinoma and effects of surveillance. Clin Gastroenterol Hepatol 2011; 9: e1.
29. Yu JC, Neugut AI, Wang S, et al,. Racial and insurance disparities in the receipt of transplant among patients with hepatocellular carcinoma. Cancer 2010; 116: 1801-9.
30. Zak Y, Rhoads KF, Visser BC,. Predictors of surgical intervention for hepatocellular carcinoma: race, socioeconomic status, and hospital type. Arch Surg 2011; 146: 778-84.
31. Zaydfudim V, Whiteside MA, Griffin MR, Feurer ID, Wright JK, Pinson CW,. Health insurance status affects staging and influences treatment strategies in patients with hepatocellular carcinoma. Ann Surg Oncol 2010; 17: 3104-11.
32. Kanwal F, Befeler A, Chari RS, et al,. Di'Bisceglie A. Potentially curative treatment in patients with hepatocellular cancer-results from the liver cancer research network. Aliment Pharmacol Ther 2012; 36: 257-65.
33. Taplin SH, Clauser S, Rodgers AB, Breslau E, Rayson D,. Interfaces across the cancer continuum offer opportunities to improve the process of care. J Natl Cancer Inst Monogr 2010; 2010: 104-10.
34. Sussman J, Baldwin LM,. The interface of primary and oncology specialty care: from diagnosis through primary treatment. J Natl Cancer Inst Monogr 2010; 2010: 18-24.
35. Taplin SH, Rodgers AB,. Toward improving the quality of cancer care: addressing the interfaces of primary and oncology-related subspecialty care. J Natl Cancer Inst Monogr 2010; 2010: 3-10.
36. Singal AG, Yopp AC, Gupta S, et al,. Failure Rates in the Hepatocellular Carcinoma Surveillance Process. Cancer Prev Res (Phila) 2012; 5: 1124-30.
37. Camma C, Di Marco V, Cabibbo G, et al,. Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems. Aliment Pharmacol Ther 2008; 28: 62-75.
38. Bruix J, Sherman M,. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
39. Kanwal F, Hoang T, Kramer J, et al,. The performance of process measures in hepatitis C. Am J Gastroenterol 2012; 107: 1512-21.
40. Singal A, Volk ML, Waljee A, et al,. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009; 30: 37-47.
41. Singal AG, Conjeevaram HS, Volk ML, et al,. Effectiveness of Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis. Cancer Epidemiol Biomarkers Prev 2012; 21: 793-9.
42. Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB,. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology 2010; 52: 132-41.
43. Singal AG, Nehra M, Adams-Huet B, et al,. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol 2013; 108: 425-32.
44. Singal AG, Yopp A,. C SS, Packer M, Lee WM, Tiro JA. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. J Gen Intern Med 2012; 27: 861-7.
45. Trevisani F, De NS, Rapaccini G, et al,. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002; 97: 734-44.
46. Singal AG, Tiro JA, Gupta S,. Improving hepatocellular carcinoma screening: applying lessons from colorectal cancer screening. Clin Gastroenterol Hepatol 2013; 11: 472-7.
47. Vernon SW, Briss PA, Tiro JA, Warnecke RB,. Some methodologic lessons learned from cancer screening research. Cancer 2004; 101: 1131-45.